An undiagnosed patient with skin rash, polyarthritis, and edema responding to low-dose colchicine: A case report

Hiroki Maita1, Tadashi Kobayashi2, Takashi Akimoto2, Hiroshi Osawa2, Keisuke Hasui3 and Hiroyuki Kato1,2,4

Abstract
A 54-year-old man was referred to our hospital with painful rashes on the extremities. He also developed polyarthritis and pitting pedal edema. Blood tests showed no specific autoantibodies and were negative for human leukocyte antigens B51, B15, and B27. Lower extremity venous ultrasonography and computed tomography angiography showed no vascular disorders. Skin biopsy showed no evidence of thrombosis or vasculitis. Direct fluorescence antibody analysis showed no antibody or complement deposition. Joint ultrasonography showed mild synovial thickening and/or synovial effusion in the extremities. Non-steroidal anti-inflammatory drugs and topical steroids were administered, followed by oral steroids. However, the signs and symptoms did not improve. Oral steroids were discontinued, and colchicine (0.5 mg/day) was administered. Thereafter, the symptoms of arthritis improved, and no skin rash developed. In potentially inflammatory conditions with skin rash, edema, and polyarthritis that are difficult to diagnose, low-dose colchicine administration may be considered for prompt relief of symptoms.

Keywords
Arthralgia, arthritis, colchicine, steroid, unclassified disease, undetermined disease, undiagnosed disease, undifferentiated disease

Date received: 5 November 2020; accepted: 24 May 2021

Introduction
Advances in medicine continue to decipher the etiology and pathophysiology of many previously unexplained diseases. However, in some patients, establishing a definitive diagnosis is difficult, even if necessary physical examination, blood tests, or imaging studies were adequately performed.1,2 Approximately 7%–35% of patients with unknown fever cannot be precisely diagnosed, and treatment may be initiated before a definitive diagnosis is established.3 In general outpatient clinics, 25%–75% of patients complain of medically unexplained physical symptoms,4 some of which may be due to unknown diseases.5 Colchicine, an alkaloid originally extracted from the autumn crocus plant, is an inexpensive and potent anti-inflammatory drug for gout.6,7 It is also prescribed in familial Mediterranean fever, Behçet’s disease, and pericarditis. Colchicine is thought to act by preventing leukocyte adhesion, mobility, and cytokine production through inhibiting tubulin polymerization and microtubule generation, thereby exerting anti-inflammatory effects.8,9

Herein, we present an undiagnosed patient with multiple symptoms and findings, including skin rash, arthritis, pitting edema of the extremities, and inflammation that responded significantly to low-dose colchicine treatment, following ineffective treatment with steroids and non-steroidal anti-inflammatory drugs (NSAIDs).

1Development of Community Healthcare, Graduate School of Medicine, Hirosaki University, Aomori, Japan
2Department of General Medicine, Graduate School of Medicine & University Hospital, Hirosaki University, Aomori, Japan
3Department of Community Medical Support, Graduate School of Medicine, Hirosaki University, Aomori, Japan
4Department of General Medicine, Graduate School of Medicine, Hirosaki University, Aomori, Japan

Corresponding Author:
Hiroki Maita, Development of Community Healthcare, Graduate School of Medicine, Hirosaki University, 5 Zaifu-cho, Hirosaki-shi, Aomori 036-8562, Japan.
Email: maita@hirosaki-u.ac.jp

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Case

A 54-year-old man with a history of alcoholic liver dysfunction and gout was referred to our hospital with rashes on his extremities (Figure 1). Five years ago, the patient had small and linear painful erythema on both lower limbs. Treatment was started with NSAIDs and topical steroids. However, the rash did not improve. Three years ago, a dermatologist suspected the patient to have erythema nodosum and/or thrombophlebitis. A year later, oral steroids were added at initial doses of 25 mg/day of prednisolone and continued at 5–20 mg/day as a maintenance dose according to symptoms. However, the symptoms did not improve. Skin rashes appeared solely along the superficial veins of the lower limbs over the sites touching footwear (boots), especially after standing in the afternoon. A year ago, similar skin rashes appeared on his upper limbs, along with pain, edema, and morning stiffness of both fingers, and he could not put on his ring. Subsequently, he began to experience pitting pedal edema and pain around the toes and heels (Figure 2). The symptoms of the affected joints were never in complete remission for more than a year without obvious joint swelling with erythema. He had no fever, weight loss, respiratory symptoms, impaired blood flow to the extremities, tophi, stomatitis, genital ulcers, folliculitis, or ocular symptoms.

Lower extremity venous ultrasonography showed no thrombus. Lower extremity computed tomography (CT) angiography showed no arterial occlusive lesions or arteriovenous shunting. Skin biopsy showed no evidence of thrombosis or vasculitis. Direct fluorescence antibody analysis showed no antibody or complement deposition. The disease’s etiology remained unknown despite a detailed examination, and the patient was referred to our hospital.

Dermatologists, gastroenterologists, rheumatologists, endocrinologists, and general practitioners participated in a multidisciplinary approach to the patient’s diagnosis and treatment. At the first visit to our hospital (Table 1), blood tests showed mild abnormalities in C-reactive protein (CRP) levels and erythrocyte sedimentation rate, with alcoholic
Table 1. Hematological and biochemical investigations at the patient's first visit and during follow-up.

| Parameters at the first visit | Results |
|-------------------------------|---------|
| White blood cell count (/μL) 6360 | Neutrophil (%) 63 |
| | Lymphocyte (%) 31.6 |
| | Monocyte (%) 4.9 |
| | Eosinophil (%) 0.2 |
| | Basophil (%) 0.3 |
| Red blood cell count (×10^6/μL) 312 | Mean corpuscular volume (fl) 103.2 |
| Mean corpuscular hemoglobin (pg) 33 | Platelet (/μL) 186,000 |
| Erythrocyte sedimentation rate (1 h/2 h) (mm) 51/86 | Prothrombin time-international normalized ratio 0.88 |
| Activated partial thromboplastin time (control) (s) 23.7 (28.1) | Lupus anticoagulant Negative |
| Total protein (g/dL) 5.7 | Albumin (g/dL) 2.9 |
| Blood urea nitrogen (mg/dL) 16 | Creatinine (mg/dL) 1 |
| Sodium (mmol/L) 141 | Potassium (mmol/L) 3.6 |
| Chloride (mmol/L) 108 | Calcium (mg/dL) 7.9 |
| Calcium (mg/dL) 7.9 | Inorganic phosphorus (mg/dL) 2.1 |
| Uric acid (mg/dL) 6.4 | Total cholesterol (mg/dL) 468 |
| Triglyceride (mg/dL) 2038 | Aspartate aminotransferase (U/L) 49 |
| Alanine aminotransferase (U/L) 28 | Alkaline phosphatase (U/L) 141 |
| Lactate dehydrogenase (U/L) 222 | Total bilirubin (mg/dL) 0.4 |
| Gamma-glutamyl transferase (U/L) 337 | C-reactive protein (mg/dL) 0.292 |
| Cholinesterase (U/L) 280 | Creatine phosphokinase (U/L) 43 |
| Glucose (mg/dL) 95 | Hemoglobin A1c (%) 5.1 |
| IgG (mg/dL) 338 | IgA (mg/dL) 105 |
| IgM (mg/dL) 117 | IgD (mg/dL) 1.5 |
| C3 (mg/dL) 97 | C4 (mg/dL) 30 |
| CH50 (U/mL) 52 | Thyroid stimulating hormone (μIU/mL) 2.01 |
| Free triiodothyronine (pg/mL) 2.74 | Free thyroxine (ng/dL) 0.74 |
| Rapid plasma reagin test Negative | Treponema pallidum latex agglutination test Negative |
| Hepatitis B e antigen Negative | Hepatitis B surface antigen Negative |

(Continued)
disease, such as B51, B15, and B27, was found. First, recommendations for abstaining from alcohol and improving diet were provided as alcoholic liver disorders treatment. The previously prescribed oral steroids were tapered off and discontinued, and colchicine 0.5 mg/day was initiated for the treatment of polyarthritis. After taking low-dose colchicine, the patient noticed a gradual improvement in pain in his extremities. No acute toxicity due to colchicine was observed. After approximately 1 month of colchicine treatment, the patient’s subjective symptoms of arthritis improved such that the pain intensity decreased to nearly one-third of the pretreatment value. The patient could put on his ring without difficulty, and his weight decreased from 64 to 62 kg. In addition, no new-onset skin rash was observed. After 6 months of colchicine treatment, CRP levels were normalized (Table 2), and the joint pain nearly disappeared; the patient only reported mild stiffness in the hand for brief periods in the morning, so he was able to lead a normal life.

Discussion

This case report highlights two important issues. First, physicians need to treat symptoms appropriately, regardless of causes, even if these are medically unexplained symptoms.10 In Japan, blood tests, ultrasonography, and biopsy are all covered by the Japanese national public health insurance. Some undiagnosed cases are referred to the Initiative on Rare and Undiagnosed Diseases led by the Japan Agency for Medical Research and Development for genetic analyses.11 This facility is not easily available in all regions of Japan. In our patient, a multidisciplinary approach was used to diagnose possible diseases, such as chronic gout, thrombophlebitis, Behçet’s disease, sarcoidosis, vasculitis, coagulopathy, nutritional disturbances, and substance abuse. Although treatment should ideally be started before establishing definitive diagnoses, physicians are often reluctant to begin it. It has been reported that symptomatic relief for even acute abdominal diseases does not delay in diagnosis.12,13 Since definitive or effective treatment does not always exist, the goal of treatment should be to provide symptomatic relief and improve daily activities.5

Second, colchicine could be effective in undiagnosed disease patients complaining of skin rashes, polyarthritis, and edema, especially those with some features similar to autoinflammatory or autoimmune diseases. Colchicine is reported to be effective in many diseases, including recurrent polychondritis,14 pyoderma gangrenosum,15 adult-onset Still’s disease,16 interstitial pneumonia,17 pericarditis, gout, and familial Mediterranean fever. Possible diagnoses of these diseases were ruled out in our case. The efficacy of low-dose colchicine in preventing cardiovascular events after myocardial infarction has also been reported,6 and its anti-inflammatory effect on atherosclerosis is currently anticipated. Colchicine is not a common treatment choice for various inflammatory arthritis that is difficult to classify. For example, patients with early persistent undifferentiated inflammatory arthritis and evaluated as being at risk of persistent arthritis are recommended to receive disease-modifying antirheumatic drugs (DMARDs) as early as possible (ideally within three months). These treatments might be administered even if patients do not meet the inflammatory rheumatologic disease criteria, and colchicine is not considered a therapeutic option.18 The guidelines for undifferentiated spondyloarthritis include DMARDs, NSAIDs, and steroids as treatment options, and colchicine is not considered a treatment choice.19 Even in the absence of a definitive diagnosis, colchicine may improve symptoms and contribute to improving the quality of life in cases with suspected abnormalities in leukocyte function or cytokine production as the pathophysiology.

Conclusion

We presented an undiagnosed patient with main symptoms of skin rash, polyarthritis, and edema. In potentially inflammatory conditions that are difficult to classify, low-dose colchicine administration could be effective in symptomatic treatment.

Author contributions

H.M. conceived the idea and wrote the original draft of the manuscript. T.K. developed the theory and supervised the findings of this study. All authors discussed the case and commented on the manuscript. H.M., T.K., and T.A. revised and edited the manuscript. All authors gave final approval before submission of the manuscript.

Data availability

The data supporting the findings of this study are available from the corresponding author upon reasonable request.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval
Our institution does not require ethical approval for reporting individual cases or case series.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent
Written informed consent was obtained from the patient for publication of this case.

ORCID iDs
Hiroki Maita https://orcid.org/0000-0001-9642-9116
Tadashi Kobayashi https://orcid.org/0000-0002-2001-4464
Keisuke Hasui https://orcid.org/0000-0003-2637-0571

References
1. Adachi T, Imanishi N, Ogawa Y, et al. Survey on patients with undiagnosed diseases in Japan: potential patient numbers benefiting from Japan’s initiative on rare and undiagnosed diseases (IRUD). Orphanet J Rare Dis 2018; 13: 208.
2. Splinter K, Adams DR, Bacino CA, et al. Effect of genetic diagnosis on patients with previously undiagnosed disease. New Eng J Med 2018; 379: 2131–2139.
3. Suzuki A, Ohosone Y, Mita S, et al. Fever of unknown origin responding to steroid therapy. Nihon Rinsho Meneki Gakkai Kaishi 1997; 20(1): 21–29.
4. Smith RC and Dwamena FC. Classification and diagnosis of patients with medically unexplained symptoms. J Gen Intern Med 2007; 22(5): 685–691.
5. Miyazaki H. The “minimum knowledge” needed by primary care physicians: medically unexplained symptoms. Nihon Naika Gakkai Zasshi 2009; 98: 188–191.
6. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. New Eng J Med 2019; 381: 2497–2505.
7. Nuki G and Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 2006; 8(Suppl. 1): S1.
8. Perico N, Ostermann D, Bontempeill M, et al. Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation. J Am Soc Nephrol 1996; 7(4): 594–601.
9. Niel E and Scherrmann JM. Colchicine today. Joint Bone Spine 2006; 73(6): 672–678.
10. Hatcher S and Arroll B. Assessment and management of medically unexplained symptoms. BMJ 2008; 336: 1124–1128.
11. Adachi T, Kawamura K, Furusawa Y, et al. Japan’s initiative on rare and undiagnosed diseases (IRUD): towards an end to the diagnostic odyssey. Eur J Hum Genet 2017; 25(9): 1025–1028.
12. Manterola C, Vial M, Moraga J, et al. Analgesia in patients with acute abdominal pain. Cochrane Database Syst Rev 2011; 1: CD005660.
13. Falch C, Vicente D, Haberle H, et al. Treatment of acute abdominal pain in the emergency room: a systematic review of the literature. Eur J Pain 2014; 18(7): 902–913.
14. Mark KA and Franks AG Jr. Colchicine and indomethacin for the treatment of relapsing polychondritis. J Am Acad Dermatol 2002; 46(2. Suppl): S22–14.
15. Kontochristopoulos GJ, Stavropoulos PG, Gregoriou S, et al. Treatment of pyoderma gangrenosum with low-dose colchicine. Dermatology 2004; 209(3): 233–236.
16. Asano T, Furuya MY, Sato S, et al. Adding colchicine to immunosuppressive treatments; a potential option for biologics-refractory adult-onset Still’s disease. BMC Res Notes 2018; 11: 15.
17. Ishizuka T, Hisada T, Monden T, et al. A case of non-specific interstitial pneumonia effectively treated with a combination of prednisolone and colchicine, in which granulation tissue was extensive. Respiratory 2005; 10(4): 541–544.
18. Combe B, Landewe R, Dauwels CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 2017; 76: 948–959.
19. NICE guidelines. Spondyloarthrits in over 16s: diagnosis and management. https://www.nice.org.uk/guidance/ng65 (2017, accessed 10 August 2020).